{"organizations": [], "uuid": "5ddfca9db97c1d47197c9c08195c43bfc16b9d68", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/aurobindo-pharm-results/aurobindo-pharma-q3-profit-up-about-3-pct-misses-estimates-idUSL4N1PX4KF", "country": "US", "domain_rank": 408, "title": "Aurobindo Pharma Q3 profit up about 3 pct, misses estimates", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T20:16:00.000+02:00", "replies_count": 0, "uuid": "5ddfca9db97c1d47197c9c08195c43bfc16b9d68"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/aurobindo-pharm-results/aurobindo-pharma-q3-profit-up-about-3-pct-misses-estimates-idUSL4N1PX4KF", "ord_in_thread": 0, "title": "Aurobindo Pharma Q3 profit up about 3 pct, misses estimates", "locations": [], "entities": {"persons": [{"name": "aby jose koilparambil", "sentiment": "none"}, {"name": "amrutha gayathri", "sentiment": "none"}, {"name": "jessica kuruthukulangara", "sentiment": "none"}], "locations": [{"name": "india", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "aurobindo pharma ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "aurobindo pharma", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Aurobindo Pharma Ltd, India’s third largest drugmaker by revenue, posted an about 3 percent rise in quarterly profit on Wednesday, but missed analysts’ estimates.\nProfit was 5.95 billion rupees ($92.6 million) in the third quarter ended Dec. 31, compared with 5.79 billion rupees a year earlier, the Hyderabad-headquartered drugmaker said. bit.ly/2FSPsfo\nAnalysts on average had expected a profit of 6.71 billion rupees, Thomson Reuters data showed.\nTotal revenue from operations rose 11 percent to 43.36 billion rupees.\n$1 = 64.2600 Indian rupees Reporting by Jessica Kuruthukulangara and Aby Jose Koilparambil in Bengaluru; Editing by Amrutha Gayathri\n ", "external_links": ["http://bit.ly/2FSPsfo", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T20:16:00.000+02:00", "crawled": "2018-02-09T05:41:46.011+02:00", "highlightTitle": ""}